Skip to content
Open access

CO078 | METABOLOMIC AND LIPOPROTEOMIC MODULATION FOLLOWING INCLISIRAN TREATMENT IN DYSLIPIDEMIC PATIENTS

Oct 2026 · Bleeding Thrombosis and Vascular Biology · 0 citations

TL;DR

Inclisiran treatment was associated with extensive and coherent reductions in lipoprotein-related parameters, and this findings reinforce the highly specific lipid-lowering mechanism of inclisiran and underscore inter-individual variability in treatment response, particularly in the context of concomitant lipid-lowering therapies.

Abstract

Background and Aims. Inclisiran is a subcutaneously administrated synthetic small interfering RNA directed against proprotein convertase subtilisin–kexin type 9, leading to sustained low-density lipoprotein cholesterol (LDL-C) reduction with a twice-yearly dosing regimen. While its lipid-lowering efficacy is well established, its broader metabolic effects remain incompletely characterized. Metabolomics refers to the comprehensive analysis of small-molecule metabolites reflecting systemic biochemical activity, whereas lipoproteomics focuses on the detailed characterization of lipoprotein particles and their subclasses, providing deeper insight into lipid transport and cardiovascular risk. This study aimed to comprehensively evaluate serum metabolomic and lipoproteomic changes in patients with dyslipidemia before and after inclisiran treatment using an integrated nuclear magnetic resonance (NMR)-based approach.Methods. This observational single-center study included 69 patients with dyslipidemia treated with inclisiran in routine clinical practice. Fasting serum samples were collected at baseline and three months after treatment initiation. A total of 30 metabolites and 112 lipoprotein-related parameters were quantified using NMR spectroscopy. Paired comparisons between time points were performed using the Wilcoxon signed-rank test with false discovery rate correction. Clustering based on lipoprotein changes was conducted using the KODAMA algorithm to identify distinct response patterns.Results. Inclisiran treatment was associated with extensive and coherent reductions in lipoprotein-related parameters. Seventy-four lipoprotein variables showed significant changes. Reductions were observed across LDL, IDL, and VLDL subclasses, while some HDL-related parameters were increased. In contrast, the global metabolomic profile remained largely unchanged; trimethylamine-N-oxide (TMAO) was the only metabolite significantly increased at follow-up. KODAMA clustering identified three patient groups with heterogeneous responses. Two groups demonstrated marked lipoprotein reductions, particularly those with higher baseline LDL-related parameters, whereas one group exhibited minimal changes. Baseline TMAO levels were lower in the group with the most pronounced lipid response and increased at follow-up, potentially reflecting changes in concomitant lipid-lowering therapy rather than a direct effect of inclisiran.Conclusions. Inclisiran induces a broad and consistent improvement in lipoprotein profiles, extending beyond LDL-C reduction, while exerting only minimal effects on the global metabolomic landscape. These findings reinforce the highly specific lipid-lowering mechanism of inclisiran and underscore inter-individual variability in treatment response, particularly in the context of concomitant lipid-lowering therapies.

Read PDF

Similar papers

Open access Oct 2026

Apolipoprotein and inflammatory biomarker changes following marked triglyceride reduction with the GalNAc-conjugated APOC3 siRNA RBD5044

Profound TG reduction achieved by APOC3 siRNA therapy is associated with an apolipoprotein pattern resembling APOC3 heterozygous deficiency, as well as a coordinated anti-inflammatory response, suggesting that deep APOC3 silencing remodels lipoprotein composition and may contribute to inflammation resolution by modulat...

S. Nilsson, S. Ueckert, A. Gabrielsen et al. · 0 citations
Open access Oct 2026

EDP167, an ANGPTL3-target siRNA, showed favorable safety and lipid-lowering potential in Chinese healthy adult volunteers and subjects with mild dyslipidemia

In healthy volunteers and subjects with mild dyslipidemia, single subcutaneous doses of EDP167 demonstrated a favorable safety and tolerability profile and a dose-dependent reduction in ANGPTL3 and substantial reductions in TG, LDL-C, non-HDL-C, ApoB and remnant-C were observed.

J. Wang, B. Jiang, Shi-Long Zhong et al. · 0 citations
Open access Jan 2026

Serum Metabolomic Profiling Reveals Potential Mechanisms and Biomarkers of Seladelpar Treatment in Patients With Primary Biliary Cholangitis

Targeted metabolomics confirmed seladelpar′s impact on carnitine and acylcarnitines, which facilitate fatty acid β‐oxidation, and highlighted potential pathways for future exploration in the treatment of PBC and its symptoms.

Yun-Jung Choi, Andrew J. Schwab, James Lim et al. · 0 citations
Open access Oct 2026

Cellular deep proteomic profiling elucidates NLRP3 inflammasome and immunothrombosis effects of GLP-1 receptor agonist: a controlled intervention study

GLP-1 receptor agonists confer pleiotropic vascular protection via mechanisms other than glycemic and body weight control. Comprehensive proteomic evaluations of its immunothrombosis modulatory and vascular effects remained limited. To investigate the immunothrombosis modulatory effects of GLP-1 receptor a...

Y. Chan, S. Rakesh, T. Chan et al. · 0 citations
Open access Oct 2026

Integrated chemical profiling and lipidomics reveal that Mailuoning oral liquid alleviates diet-induced MASLD via PPARα-mediated lipid homeostasis and COX-2 inhibition, with identification of potential active constituents

Mailuoning oral liquid (MLN), a standardized five-herb formula, is used for ischemic vascular diseases and shows potential in ameliorating dyslipidemia. Our previous study showed MLN alleviates metabolic dysfunction-associated steatotic liver disease (MASLD) via peroxisome proliferator-activated receptor α (PPARα)...

Si-Jia Wu, Wang-Ya Jia, Xun Zhou et al. · 0 citations
Open access Oct 2026

Atorvastatin-Curcuminoids Co-Treatment Suppresses ApoB Secretion and Alters Lipid and Glucose Homeostasis in HuH-7 Cells

ATO-curcuminoid co-treatment suppressed ApoB secretion but was accompanied by increased intracellular lipid accumulation, altered glucose uptake and GLUT2 expression, and apoptosis, indicating a discordant hepatic response.

A. Bakillah, Haidar A. Alsahoud, Abeer Al Otaibi et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.